Clinical trial
MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
NCT03017820 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 4, 2017
- Completion date
- April 1, 2032
- Enrollment
- 99 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell non-hodgkin lymphoma, histiocytic and dendritic cell neoplasm, myelodysplastic syndrome, previously treated myelodysplastic syndrome, recurrent adult acute myeloid leukemia, recurrent anaplastic large cell lymphoma, recurrent angioimmunoblastic t-cell lymphoma, recurrent mycosis fungoides, recurrent plasma cell myeloma, recurrent primary cutaneous t-cell non-hodgkin lymphoma, recurrent t-cell non-hodgkin lymphoma, refractory acute myeloid leukemia, refractory anaplastic large cell lymphoma, refractory angioimmunoblastic t-cell lymphoma, refractory mycosis fungoides, refractory peripheral t-cell lymphoma, not otherwise specified, refractory plasma cell myeloma, refractory primary cutaneous t-cell non-hodgkin lymphoma, refractory t-cell non-hodgkin lymphoma